schliessen

Filtern

 

Bibliotheken

Drug Management of Obesity — Efficacy versus Safety

The history of pharmacologic treatment of obesity is characterized by repetition: most drugs that have achieved regulatory approval and reached the markets have subsequently been withdrawn owing to postmarketing discovery of serious adverse effects. In 2007, the cannabinoid-receptor antagonist rimon... Full description

Journal Title: The New England Journal of Medicine 2010, Vol.363(3), pp.288-290
Main Author: Astrup, Arne
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 0028-4793 ; E-ISSN: 1533-4406 ; DOI: 10.1056/NEJMe1004076
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: nejm10.1056/NEJMe1004076
title: Drug Management of Obesity — Efficacy versus Safety
format: Article
creator:
  • Astrup, Arne
subjects:
  • Anti-Obesity Agents–Adverse Effects
  • Anti-Obesity Agents–Contraindications
  • Anti-Obesity Agents–Therapeutic Use
  • Benzazepines–Adverse Effects
  • Benzazepines–Therapeutic Use
  • Cyclobutanes–Contraindications
  • Drug Approval–Legislation & Jurisprudence
  • Fenfluramine–Adverse Effects
  • Humans–Drug Therapy
  • Obesity–Drug Therapy
  • Overweight–Therapeutic Use
  • Serotonin 5-Ht2 Receptor Agonists–Drug Effects
  • Serotonin Receptor Agonists–Drug Effects
  • United States–Drug Effects
  • United States Food & Drug Administration–Drug Effects
  • Weight Loss–Drug Effects
  • United States–Us
  • Drug Therapy
  • Cardiovascular Disease
  • Heart
  • Serotonin
  • FDA Approval
  • Regulatory Approval
  • Anti-Obesity Agents
  • Benzazepines
  • Cyclobutanes
  • Serotonin 5-Ht2 Receptor Agonists
  • Serotonin Receptor Agonists
  • Fenfluramine
  • Lorcaserin
  • Sibutramine
ispartof: The New England Journal of Medicine, 2010, Vol.363(3), pp.288-290
description: The history of pharmacologic treatment of obesity is characterized by repetition: most drugs that have achieved regulatory approval and reached the markets have subsequently been withdrawn owing to postmarketing discovery of serious adverse effects. In 2007, the cannabinoid-receptor antagonist rimonabant was not approved by the Food and Drug Administration (FDA) and was withdrawn from the market in Europe because of an increased risk of depression, anxiety, and suicidal ideation 1 ; the development program for several compounds of the same class that were in phase 3 studies had to be terminated. In January of this year, the European Medicine Agency's Committee . . .
language:
source:
identifier: ISSN: 0028-4793 ; E-ISSN: 1533-4406 ; DOI: 10.1056/NEJMe1004076
fulltext: fulltext
issn:
  • 0028-4793
  • 00284793
  • 1533-4406
  • 15334406
url: Link


@attributes
ID1085865184
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1056/NEJMe1004076
sourceidnejm
recordidTN_nejm10.1056/NEJMe1004076
sourceformatXML
sourcesystemOther
pqid612802587
galeid234019194
display
typearticle
titleDrug Management of Obesity — Efficacy versus Safety
creatorAstrup, Arne
ispartofThe New England Journal of Medicine, 2010, Vol.363(3), pp.288-290
identifier
descriptionThe history of pharmacologic treatment of obesity is characterized by repetition: most drugs that have achieved regulatory approval and reached the markets have subsequently been withdrawn owing to postmarketing discovery of serious adverse effects. In 2007, the cannabinoid-receptor antagonist rimonabant was not approved by the Food and Drug Administration (FDA) and was withdrawn from the market in Europe because of an increased risk of depression, anxiety, and suicidal ideation 1 ; the development program for several compounds of the same class that were in phase 3 studies had to be terminated. In January of this year, the European Medicine Agency's Committee . . .
source
subjectAnti-Obesity Agents–Adverse Effects ; Anti-Obesity Agents–Contraindications ; Anti-Obesity Agents–Therapeutic Use ; Benzazepines–Adverse Effects ; Benzazepines–Therapeutic Use ; Cyclobutanes–Contraindications ; Drug Approval–Legislation & Jurisprudence ; Fenfluramine–Adverse Effects ; Humans–Drug Therapy ; Obesity–Drug Therapy ; Overweight–Therapeutic Use ; Serotonin 5-Ht2 Receptor Agonists–Drug Effects ; Serotonin Receptor Agonists–Drug Effects ; United States–Drug Effects ; United States Food & Drug Administration–Drug Effects ; Weight Loss–Drug Effects ; United States–Us ; Drug Therapy ; Cardiovascular Disease ; Heart ; Serotonin ; FDA Approval ; Regulatory Approval ; Anti-Obesity Agents ; Benzazepines ; Cyclobutanes ; Serotonin 5-Ht2 Receptor Agonists ; Serotonin Receptor Agonists ; Fenfluramine ; Lorcaserin ; Sibutramine;
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontribAstrup, Arne
titleDrug Management of Obesity — Efficacy versus Safety
descriptionThe history of pharmacologic treatment of obesity is characterized by repetition: most drugs that have achieved regulatory approval and reached the markets have subsequently been withdrawn owing to postmarketing discovery of serious adverse effects. In 2007, the cannabinoid-receptor antagonist rimonabant was not approved by the Food and Drug Administration (FDA) and was withdrawn from the market in Europe because of an increased risk of depression, anxiety, and suicidal ideation 1 ; the development program for several compounds of the same class that were in phase 3 studies had to be terminated. In January of this year, the European Medicine Agency's Committee . . .
general
010.1056/NEJMe1004076
1Massachusetts Medical Society
sourceidnejm
recordidnejm10.1056/NEJMe1004076
issn
00028-4793
100284793
21533-4406
315334406
rsrctypearticle
creationdate2010
addtitleThe New England Journal of Medicine
searchscopenejm
scopenejm
lsr30VSR-Enriched:[pqid, subject, pages, galeid]
sort
titleDrug Management of Obesity — Efficacy versus Safety
authorAstrup, Arne
creationdate20100715
facets
frbrgroupid9076457117456629771
frbrtype5
creationdate2010
collectionNEJM (New England Journal of Medicine)
prefilterarticles
rsrctypearticles
creatorcontribAstrup, Arne
jtitleThe New England Journal of Medicine
toplevelpeer_reviewed
frbr
t2
k12010
k2
000284793
115334406
k310.1056/NEJMe1004076
k4363
k53
k6288
k7new england journal of medicine
k8drug management of obesity — efficacy versus safety
k9drugmanagementofobesafety
k12drugmanagementofobesity—e
k15arneastrup
k16astruparne
delivery
delcategoryRemote Search Resource
fulltextfulltext
ranking
booster11
booster21
addata
aulastAstrup
aufirstArne
auAstrup, Arne
atitleDrug Management of Obesity — Efficacy versus Safety
jtitleThe New England Journal of Medicine
risdate20100715
volume363
issue3
spage288
epage290
issn0028-4793
eissn1533-4406
formatjournal
genrearticle
ristypeJOUR
abstractThe history of pharmacologic treatment of obesity is characterized by repetition: most drugs that have achieved regulatory approval and reached the markets have subsequently been withdrawn owing to postmarketing discovery of serious adverse effects. In 2007, the cannabinoid-receptor antagonist rimonabant was not approved by the Food and Drug Administration (FDA) and was withdrawn from the market in Europe because of an increased risk of depression, anxiety, and suicidal ideation 1 ; the development program for several compounds of the same class that were in phase 3 studies had to be terminated. In January of this year, the European Medicine Agency's Committee . . .
pubMassachusetts Medical Society
doi10.1056/NEJMe1004076
pages288-90
date2010-07-15